,published_date,market,entry_time,exit_time,ticker,direction,shares,entry_price,exit_price,target_price,stop_price,hit_target,hit_stop,pnl,pnl_pct,capital_after,news_event,link
0,2025-05-28T22:40:00.000Z,after_market,2025-05-29T14:26:00.000Z,2025-05-29T14:26:00.000Z,TSHA,LONG,344,2.9049999713897705,2.8904749715328215,2.934049971103668,2.8904749715328215,false,true,-4.996599950790454,-0.4996599950790454,9995.003400049209,shares_issue,https://www.globenewswire.com/news-release/2025/05/29/3090036/0/en/Taysha-Gene-Therapies-Announces-Pricing-of-Public-Offering-of-Common-Stock-and-Pre-Funded-Warrants.html
1,2025-05-29T08:00:00.000Z,pre_market,2025-05-29T14:26:00.000Z,2025-05-29T14:29:00.000Z,VXRT,SHORT,2126,0.4700999855995178,0.47245048552751534,0.4653989857435226,0.47245048552751534,false,true,-4.997162846922723,-0.49996609775021394,9990.006237202286,corporate_action,https://www.globenewswire.com/news-release/2025/05/29/3090286/25416/en/Vaxart-s-Founder-and-Chief-Scientific-Officer-Provides-Video-Update-to-Stockholders.html
2,2025-05-30T07:30:00.000Z,pre_market,2025-05-30T14:26:00.000Z,2025-05-30T15:12:00.000Z,TGTX,LONG,28,35.029998779296875,35.38029876708985,35.38029876708985,34.85484878540039,true,false,9.808399658203228,0.9818211746132085,9999.814636860488,clinical_study,https://www.globenewswire.com/news-release/2025/05/30/3090994/8790/en/TG-Therapeutics-Announces-Data-Presentations-for-BRIUMVI-in-Multiple-Sclerosis-at-the-2025-Consortium-of-Multiple-Sclerosis-Centers-Annual-Meeting.html
3,2025-05-30T08:00:00.000Z,pre_market,2025-05-30T14:26:00.000Z,2025-05-30T14:28:00.000Z,MDAI,LONG,613,1.6292999982833862,1.6211534982919693,1.64559299826622,1.6211534982919693,false,true,-4.993804494738574,-0.49938970631823765,9994.820832365749,management_changes,https://www.globenewswire.com/news-release/2025/05/30/3091011/0/en/Spectral-AI-Announces-Appointment-of-Stanley-Micek-as-Chief-Operating-Officer.html
4,2025-06-02T06:45:00.000Z,pre_market,2025-06-02T14:26:00.000Z,2025-06-02T14:26:00.000Z,BNTX,LONG,8,113.09500122070312,112.52952621459961,114.22595123291016,112.52952621459961,false,true,-4.523800048828093,-0.4526144214790613,9990.297032316921,partnerships,https://www.globenewswire.com/news-release/2025/06/02/3091688/0/en/BioNTech-and-Bristol-Myers-Squibb-Announce-Global-Strategic-Partnership-to-Co-Develop-and-Co-Commercialize-Next-generation-Bispecific-Antibody-Candidate-BNT327-Broadly-for-Multiple.html
5,2025-06-02T06:45:00.000Z,pre_market,2025-06-02T14:26:00.000Z,2025-06-02T14:26:00.000Z,BNTX,LONG,8,113.09500122070312,112.52952621459961,114.22595123291016,112.52952621459961,false,true,-4.523800048828093,-0.4528193740580851,9985.773232268093,partnerships,https://www.globenewswire.com/news-release/2025/06/02/3091688/0/de/BioNTech-und-Bristol-Myers-Squibb-geben-globale-strategische-Partnerschaft-zur-gemeinsamen-Entwicklung-und-Kommerzialisierung-des-bispezifischen-Antik%C3%B6rperkandidaten-BNT327-in-eine.html
6,2025-06-02T07:30:00.000Z,pre_market,2025-06-02T14:26:00.000Z,2025-06-02T15:06:00.000Z,INAB,LONG,7479,0.13349999487400055,0.13483499482274056,0.13483499482274056,0.13283249489963053,true,false,9.984464616626509,0.9998689519968913,9995.757696884719,clinical_study,https://www.globenewswire.com/news-release/2025/06/02/3091745/0/en/IN8bio-Presents-Positive-Phase-1-Data-of-INB-200-in-Newly-Diagnosed-GBM-Demonstrating-Prolonged-Progression-Free-Survival.html
7,2025-06-02T08:00:00.000Z,pre_market,2025-06-02T14:26:00.000Z,2025-06-02T14:49:00.000Z,HUMA,LONG,368,2.7100000381469727,2.6964500379562377,2.7371000385284425,2.6964500379562377,false,true,-4.986400070190456,-0.49885163500356944,9990.771296814528,clinical_study,https://www.globenewswire.com/news-release/2025/06/02/3091791/0/en/Humacyte-Clinical-Results-in-High-Risk-Dialysis-Patients-from-V007-Pivotal-Phase-3.html
8,2025-06-02T08:00:00.000Z,pre_market,2025-06-02T14:26:00.000Z,2025-06-02T14:26:00.000Z,BCAB,LONG,2063,0.48420000076293945,0.4817790007591248,0.48904200077056886,0.4817790007591248,false,true,-4.994523007869679,-0.49991365626216866,9985.776773806658,clinical_study,https://www.globenewswire.com/news-release/2025/06/02/3091818/0/en/BioAtla-Presents-Phase-2-Ozuriftamab-Vedotin-Oz-V-Clinical-Trial-Data-Demonstrating-Compelling-Antitumor-Activity-in-HPV-Associated-Oropharyngeal-Squamous-Cell-Carcinoma-HPV-OPSCC-.html
9,2025-06-02T08:05:00.000Z,pre_market,2025-06-02T14:26:00.000Z,2025-06-02T14:29:00.000Z,IMNN,LONG,366,2.7249999046325684,2.752249903678894,2.752249903678894,2.7113749051094054,true,false,9.97349965095514,0.9987705390246935,9995.750273457614,clinical_study,https://www.globenewswire.com/news-release/2025/06/02/3091830/0/en/IMUNON-CEO-RECAPS-A-YEAR-OF-CLINICAL-ACHIEVEMENT-AND-SOLID-FUNDAMENTALS.html
10,2025-06-02T08:35:00.000Z,pre_market,2025-06-02T14:26:00.000Z,2025-06-02T14:28:00.000Z,DYAI,LONG,970,1.0299999713897705,1.0402999711036682,1.0402999711036682,1.0248499715328216,true,false,9.99099972248079,0.9995247429310596,10005.741273180094,management_changes,https://www.globenewswire.com/news-release/2025/06/02/3091869/0/en/Dyadic-Announces-Leadership-Change-as-Part-of-Ongoing-Strategic-Shift-to-Focus-on-High-Demand-Ancillary-Proteins-for-Life-Sciences-Nutrition-and-Industrial-Applications.html
11,2025-06-02T09:29:00.000Z,pre_market,2025-06-02T14:26:00.000Z,2025-06-02T14:32:00.000Z,IOVA,LONG,566,1.7649999856948853,1.7561749857664108,1.782649985551834,1.7561749857664108,false,true,-4.994949959516515,-0.4992083867794221,10000.746323220577,clinical_study,https://www.globenewswire.com/news-release/2025/06/02/3091973/0/en/The-Journal-of-Clinical-Oncology-Publishes-Five-year-Analysis-of-Amtagvi-lifileucel-in-Patients-with-Advanced-Melanoma.html
12,2025-06-02T16:05:00.000Z,regular_market,2025-06-02T16:10:00.000Z,2025-06-02T16:20:00.000Z,XFOR,LONG,252,3.962599992752075,3.942786992788315,4.002225992679596,3.942786992788315,false,true,-4.9928759908675655,-0.4992503388746782,9995.75344722971,changes_in_companys_own_shares,https://www.globenewswire.com/news-release/2025/06/02/3092328/0/en/X4-Pharmaceuticals-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html
13,2025-06-03T08:00:00.000Z,pre_market,2025-06-03T14:26:00.000Z,2025-06-03T14:28:00.000Z,JSPR,SHORT,163,6.099999904632568,6.13049990415573,6.038999905586243,6.13049990415573,false,true,-4.971499922275381,-0.4973611992854041,9990.781947307434,clinical_study,https://www.globenewswire.com/news-release/2025/06/03/3092716/0/en/Jasper-Therapeutics-Announces-Briquilimab-Presentations-at-the-European-Academy-of-Allergy-and-Clinical-Immunology-EAACI-Annual-Congress.html
14,2025-06-03T08:05:00.000Z,pre_market,2025-06-03T14:26:00.000Z,2025-06-03T14:26:00.000Z,IMNN,LONG,393,2.541100025177002,2.528394525051117,2.566511025428772,2.528394525051117,false,true,-4.993261549472851,-0.4997868611093609,9985.788685757962,clinical_study,https://www.globenewswire.com/news-release/2025/06/03/3092724/0/en/IMUNON-Announces-Data-Presented-at-ASCO-Reinforces-Unprecedented-Overall-Survival-in-Ovarian-Cancer-Phase-2-Study.html
15,2025-06-03T09:15:00.000Z,pre_market,2025-06-03T14:26:00.000Z,2025-06-03T14:27:00.000Z,RENB,LONG,3153,0.3167000114917755,0.3151165114343166,0.3198670116066933,0.3151165114343166,false,true,-4.992775681167869,-0.4999881169415009,9980.795910076793,patents,https://www.globenewswire.com/news-release/2025/06/03/3092863/0/en/Renovaro-Secures-Key-U-S-Patent-to-Strengthen-AI-Driven-Drug-Discovery-and-Diagnostics-Platform.html
16,2025-06-03T09:15:00.000Z,pre_market,2025-06-03T14:26:00.000Z,2025-06-03T14:28:00.000Z,EVAX,LONG,381,2.615000009536743,2.6019250094890594,2.6411500096321108,2.6019250094890594,false,true,-4.981575018167529,-0.4991160086880486,9975.814335058625,clinical_study,https://www.globenewswire.com/news-release/2025/06/03/3092866/0/en/Evaxion-receives-grant-funding-to-design-new-polio-vaccine.html
17,2025-06-03T14:55:00.000Z,regular_market,2025-06-03T15:00:00.000Z,2025-06-03T15:20:00.000Z,IMMX,LONG,399,2.4944000244140625,2.5193440246582033,2.5193440246582033,2.4819280242919923,true,false,9.952656097412174,0.9976785616824216,9985.766991156037,clinical_study,https://www.globenewswire.com/news-release/2025/06/03/3093133/0/en/Immix-Biopharma-Announces-Primary-Endpoint-Met-in-positive-NXC-201-Interim-Results-Presented-at-ASCO-Enabling-Path-to-Best-in-Class-Therapy-for-relapsed-refractory-AL-Amyloidosis.html
18,2025-06-03T16:05:00.000Z,regular_market,2025-06-03T16:10:00.000Z,2025-06-03T16:16:00.000Z,ANAB,LONG,41,23.969999313354492,23.850149316787718,24.209699306488037,23.850149316787718,false,true,-4.913849859237747,-0.49208537146818376,9980.853141296799,clinical_study,https://www.globenewswire.com/news-release/2025/06/03/3093190/0/en/Anaptys-Announces-Positive-Rosnilimab-Data-Updated-Through-Six-Months-in-Robust-Phase-2b-Trial-in-RA.html
19,2025-06-03T16:05:00.000Z,regular_market,2025-06-03T16:10:00.000Z,2025-06-03T16:42:00.000Z,WINT,LONG,1263,0.789900004863739,0.7977990049123764,0.7977990049123764,0.7859505048394203,true,false,9.976437061429058,0.9995575448506031,9990.829578358227,corporate_action,https://www.globenewswire.com/news-release/2025/06/03/3093194/0/en/Windtree-Announces-Plan-for-Cryptocurrency-Treasury-Policy.html
20,2025-06-03T16:30:00.000Z,regular_market,2025-06-03T16:35:00.000Z,2025-06-03T16:48:00.000Z,DBVT,SHORT,124,8.00790023803711,7.927821235656738,7.927821235656738,8.047939739227294,true,false,9.929796295166007,0.9938910695339624,10000.759374653393,regulatory_filings,https://www.globenewswire.com/news-release/2025/06/03/3093208/0/en/DBV-Technologies-announces-the-filing-of-an-addendum-to-the-2024-Universal-Registration-Document.html
21,2025-06-03T17:00:00.000Z,regular_market,2025-06-03T17:05:00.000Z,2025-06-03T20:56:00.000Z,OCS,LONG,51,19.31999969482422,19.440000534057617,19.51319969177246,19.223399696350096,false,false,6.12004280090332,0.611957809565379,10006.879417454296,changes_in_companys_own_shares,https://www.globenewswire.com/news-release/2025/06/03/3093227/0/en/Oculis-Publishes-Notifications-of-Transactions-by-Persons-Discharging-Managerial-Responsibilities.html
22,2025-06-03T17:17:00.000Z,regular_market,2025-06-03T17:20:00.000Z,2025-06-03T17:27:00.000Z,TSHA,LONG,345,2.8949999809265137,2.880524981021881,2.9239499807357787,2.880524981021881,false,true,-4.993874967098297,-0.4990441833832665,10001.885542487198,clinical_study,https://www.globenewswire.com/news-release/2025/06/03/3093240/0/en/Taysha-Gene-Therapies-Announces-Details-for-Oral-Presentations-at-the-2025-IRSF-Rett-Syndrome-Scientific-Meeting-Reviewing-Recent-Updates-from-the-TSHA-102-Clinical-Program.html
23,2025-06-04T06:55:00.000Z,pre_market,2025-06-04T14:26:00.000Z,2025-06-04T16:40:00.000Z,RVVTF,SHORT,44022,0.02271999977529049,0.02283359977416694,0.022492799777537584,0.02283359977416694,false,true,-5.000899150539049,-0.49999563875187686,9996.88464333666,product_services_announcement,https://www.globenewswire.com/news-release/2025/06/04/3093409/0/en/Revive-Therapeutics-Advances-with-Next-Generation-Bucillamine-Development.html
24,2025-06-04T08:00:00.000Z,pre_market,2025-06-04T14:26:00.000Z,2025-06-04T14:29:00.000Z,ELTX,LONG,117,8.5,8.585,8.585,8.4575,true,false,9.9450000000001,0.99480991877093,10006.82964333666,financing_agreements,https://www.globenewswire.com/news-release/2025/06/04/3093507/0/en/Elicio-Therapeutics-Secures-10-Million-in-Financing.html
25,2025-06-04T11:32:00.000Z,pre_market,2025-06-04T14:26:00.000Z,2025-06-04T14:53:00.000Z,ALVO,LONG,87,11.489999771118164,11.432549772262574,11.604899768829346,11.432549772262574,false,true,-4.998149900436358,-0.4994738672067354,10001.831493436222,shares_issue,https://www.globenewswire.com/news-release/2025/06/04/3093802/0/en/Alvotech-intends-to-carry-out-a-private-placement-of-approximately-7-5-million-SDRs-and-ordinary-shares.html
26,2025-06-04T16:32:00.000Z,regular_market,2025-06-04T16:35:00.000Z,2025-06-04T16:39:00.000Z,DBVT,SHORT,125,7.974999904632568,8.01487490415573,7.895249905586242,8.01487490415573,false,true,-4.984374940395275,-0.4983462222560247,9996.847118495827,regulatory_filings,https://www.globenewswire.com/news-release/2025/06/04/3094008/0/fr/Information-relative-au-nombre-total-des-droits-de-vote-et-d-actions-composant-le-capital-social-au-30-mai-2025.html
27,2025-06-04T22:29:00.000Z,after_market,2025-06-05T14:26:00.000Z,2025-06-05T14:49:00.000Z,ALVO,SHORT,91,10.880000114440918,10.771200113296509,10.771200113296509,10.934400115013121,true,false,9.900800104141261,0.9903922693609204,10006.74791859997,shares_issue,https://www.globenewswire.com/news-release/2025/06/05/3094086/0/en/Alvotech-has-carried-out-a-private-placement-of-7-500-000-SDRs-and-ordinary-shares-at-a-price-of-SEK-100-00-per-SDR-and-ISK-1320-83-per-ordinary-share-raising-gross-proceeds-of-SEK.html
28,2025-06-05T02:55:00.000Z,after_market,2025-06-05T14:26:00.000Z,2025-06-05T14:43:00.000Z,ALVO,LONG,91,10.880000114440918,10.825600113868713,10.988800115585327,10.825600113868713,false,true,-4.950400052070631,-0.49470618150269485,10001.797518547899,partnerships,https://www.globenewswire.com/news-release/2025/06/05/3094121/0/is/Alvotech-og-Dr-Reddys-ganga-til-samstarfs-um-%C3%BEr%C3%B3un-hli%C3%B0st%C3%A6%C3%B0u-vi%C3%B0-krabbameinslyfi%C3%B0-Keytruda.html
29,2025-06-05T02:55:00.000Z,after_market,2025-06-05T14:26:00.000Z,2025-06-05T14:43:00.000Z,ALVO,LONG,91,10.880000114440918,10.825600113868713,10.988800115585327,10.825600113868713,false,true,-4.950400052070631,-0.49495103684016084,9996.847118495829,licensing_agreements,https://www.globenewswire.com/news-release/2025/06/05/3094121/0/en/Alvotech-and-Dr-Reddy-s-Enter-into-Collaboration-to-Co-Develop-Biosimilar-Candidate-to-Keytruda-pembrolizumab.html
30,2025-06-05T02:55:00.000Z,after_market,2025-06-05T14:26:00.000Z,2025-06-05T14:43:00.000Z,ALVO,LONG,91,10.880000114440918,10.825600113868713,10.988800115585327,10.825600113868713,false,true,-4.950400052070631,-0.4951961346804601,9991.896718443759,licensing_agreements,https://www.globenewswire.com/news-release/2025/06/05/3094122/0/en/Alvotech-and-Dr-Reddy-s-Enter-into-Collaboration-to-Co-Develop-Biosimilar-Candidate-to-Keytruda-pembrolizumab.html
31,2025-06-05T07:02:00.000Z,pre_market,2025-06-05T14:26:00.000Z,2025-06-05T14:27:00.000Z,OCGN,LONG,994,1.0049999952316284,0.9999749952554703,1.0150499951839447,0.9999749952554703,false,true,-4.99484997630118,-0.49989007263068763,9986.901868467457,licensing_agreements,https://www.globenewswire.com/news-release/2025/06/05/3094247/0/en/Ocugen-Inc-Announces-Signing-of-Binding-Term-Sheet-for-the-License-of-OCU400-Modifier-Gene-Therapy-for-Retinitis-Pigmentosa-in-Korea.html
32,2025-06-05T07:30:00.000Z,pre_market,2025-06-05T14:26:00.000Z,2025-06-05T14:26:00.000Z,OVID,LONG,3150,0.31700000166893005,0.3154150016605854,0.3201700016856194,0.3154150016605854,false,true,-4.992750026285683,-0.49992981727894426,9981.909118441172,clinical_study,https://www.globenewswire.com/news-release/2025/06/05/3094269/0/en/Ovid-Therapeutics-to-Host-Investor-and-Media-Event-Thursday-June-12-2025.html
33,2025-06-05T08:00:00.000Z,pre_market,2025-06-05T14:26:00.000Z,2025-06-05T14:28:00.000Z,PCRX,LONG,37,26.639999389648438,26.506799392700195,26.906399383544922,26.506799392700195,false,true,-4.9283998870849715,-0.4937331955847958,9976.980718554087,changes_in_companys_own_shares,https://www.globenewswire.com/news-release/2025/06/05/3094300/0/en/Pacira-BioSciences-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html
34,2025-06-05T08:19:00.000Z,pre_market,2025-06-05T14:26:00.000Z,2025-06-05T15:03:00.000Z,BMRA,LONG,314,3.1700000762939453,3.1541500759124754,3.2017000770568846,3.1541500759124754,false,true,-4.976900119781544,-0.49883830190490946,9972.003818434305,clinical_study,https://www.globenewswire.com/news-release/2025/06/05/3094356/0/en/Biomerica-s-inFoods-IBS-Clinical-Study-Results-Published-in-June-Issue-of-Gastroenterology.html
35,2025-06-05T11:45:00.000Z,pre_market,2025-06-05T14:26:00.000Z,2025-06-05T15:47:00.000Z,VALN,LONG,160,6.210000038146973,6.272100038528443,6.272100038528443,6.178950037956238,true,false,9.936000061035202,0.9963895162843253,9981.93981849534,clinical_study,https://www.globenewswire.com/news-release/2025/06/05/3094602/0/fr/Valneva-annonce-des-r%C3%A9sultats-positifs-de-Phase-2-%C3%A0-six-mois-sur-la-persistance-des-anticorps-et-l-innocuit%C3%A9-de-son-vaccin-%C3%A0-dose-unique-contre-le-chikungunya-IXCHIQ-chez-les-enfan.html
36,2025-06-05T11:45:00.000Z,pre_market,2025-06-05T14:26:00.000Z,2025-06-05T15:47:00.000Z,VALN,SHORT,160,6.210000038146973,6.241050038337707,6.147900037765503,6.241050038337707,false,true,-4.968000030517459,-0.49769885621954446,9976.971818464823,clinical_study,https://www.globenewswire.com/news-release/2025/06/05/3094602/0/en/Valneva-Reports-Positive-Six-Month-Antibody-Persistence-and-Safety-Phase-2-Results-in-Children-for-its-Single-Shot-Chikungunya-Vaccine-IXCHIQ.html
37,2025-06-05T12:05:00.000Z,pre_market,2025-06-05T14:26:00.000Z,2025-06-05T14:34:00.000Z,SCLX,LONG,146,6.800000190734863,6.868000192642212,6.868000192642212,6.766000189781189,true,false,9.92800027847289,0.995091542716268,9986.899818743295,clinical_study,https://www.globenewswire.com/news-release/2025/06/05/3094624/0/en/Scilex-Holding-Company-Announces-Publication-on-GLOPERBA-Dosing-Adjustments-in-Peer-Review-Journal.html
38,2025-06-05T16:01:00.000Z,regular_market,2025-06-05T16:05:00.000Z,2025-06-05T16:10:00.000Z,NTLA,LONG,127,7.84499979019165,7.805774791240692,7.923449788093567,7.805774791240692,false,true,-4.981574866771707,-0.49881093804729537,9981.918243876524,changes_in_companys_own_shares,https://www.globenewswire.com/news-release/2025/06/05/3094754/0/en/Intellia-Therapeutics-Reports-Inducement-Grants-under-Nasdaq-Listing-Rule-5635-c-4.html
39,2025-06-06T01:00:00.000Z,after_market,2025-06-06T14:26:00.000Z,2025-06-06T15:28:00.000Z,ADXN,LONG,114,8.739999771118164,8.827399768829347,8.827399768829347,8.696299772262574,true,false,9.963599739074812,0.9981648312123824,9991.881843615598,clinical_study,https://www.globenewswire.com/news-release/2025/06/06/3094874/0/en/Addex-GABAB-PAM-Candidate-Demonstrates-Robust-Anti-Tussive-Activity-in-Multiple-Chronic-Cough-Preclinical-Models.html
40,2025-06-06T08:00:00.000Z,pre_market,2025-06-06T14:26:00.000Z,2025-06-06T14:38:00.000Z,TSHA,LONG,335,2.9749999046325684,2.9601249051094056,3.0047499036788943,2.9601249051094056,false,true,-4.983124840259516,-0.49871735057030603,9986.89871877534,changes_in_companys_own_shares,https://www.globenewswire.com/news-release/2025/06/06/3095044/0/en/Taysha-Gene-Therapies-Announces-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html
41,2025-06-06T08:05:00.000Z,pre_market,2025-06-06T14:26:00.000Z,2025-06-06T14:41:00.000Z,CADL,LONG,172,5.78000020980835,5.837800211906433,5.837800211906433,5.751100208759308,true,false,9.94160036087041,0.9954642217588761,9996.84031913621,management_changes,https://www.globenewswire.com/news-release/2025/06/06/3095060/0/en/Candel-Therapeutics-Appoints-Maha-Radhakrishnan-M-D-to-its-Board-of-Directors.html
42,2025-06-06T09:30:00.000Z,pre_market,2025-06-06T14:26:00.000Z,2025-06-06T14:45:00.000Z,BMRA,SHORT,315,3.1700000762939453,3.1858500766754148,3.138300075531006,3.1858500766754148,false,true,-4.992750120162874,-0.49943281684770163,9991.847569016047,management_changes,https://www.globenewswire.com/news-release/2025/06/06/3095149/0/en/Biomerica-Appoints-Eric-B-Chin-to-Board-of-Directors-and-Audit-Committee-Chair.html
43,2025-06-06T16:00:00.000Z,regular_market,2025-06-06T16:05:00.000Z,2025-06-06T17:00:00.000Z,ARQT,LONG,71,13.960000038146973,14.099600038528443,14.099600038528443,13.890200037956237,true,false,9.911600027084411,0.9919686983435899,10001.75916904313,changes_in_companys_own_shares,https://www.globenewswire.com/news-release/2025/06/06/3095428/0/en/Arcutis-Biotherapeutics-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html
44,2025-06-06T16:30:00.000Z,regular_market,2025-06-06T16:35:00.000Z,2025-06-06T16:44:00.000Z,ORIC,LONG,102,9.789999961853027,9.887899961471557,9.887899961471557,9.741049962043762,true,false,9.985799961090073,0.9984043599047601,10011.744969004221,changes_in_companys_own_shares,https://www.globenewswire.com/news-release/2025/06/06/3095449/0/en/ORIC-Pharmaceuticals-Reports-Inducement-Grants-under-Nasdaq-Listing-Rule-5635-c-4.html
45,2025-06-09T07:00:00.000Z,pre_market,2025-06-09T14:26:00.000Z,2025-06-09T14:32:00.000Z,INAB,SHORT,316,3.1600000858306885,3.1284000849723816,3.1284000849723816,3.1758000862598417,true,false,9.985600271224959,0.9973885973064431,10021.730569275447,clinical_study,https://www.globenewswire.com/news-release/2025/06/09/3095724/0/en/IN8bio-Recognizes-Achievement-of-4-Years-in-Remission-for-Patient-Treated-with-INB-200-in-Glioblastoma-Trial.html
46,2025-06-09T07:30:00.000Z,pre_market,2025-06-09T14:26:00.000Z,2025-06-09T14:30:00.000Z,PYPD,LONG,267,3.740000009536743,3.7213000094890596,3.7774000096321108,3.7213000094890596,false,true,-4.992900012731514,-0.49820736830011303,10016.737669262715,clinical_study,https://www.globenewswire.com/news-release/2025/06/09/3095757/0/en/PolyPid-Announces-Positive-Topline-Results-from-Phase-3-SHIELD-II-Trial-D-PLEX-Demonstrated-Significant-Reduction-in-Surgical-Site-Infections-and-Successfully-Met-Primary-and-All-K.html
47,2025-06-09T08:00:00.000Z,pre_market,2025-06-09T14:26:00.000Z,2025-06-09T14:32:00.000Z,HUMA,LONG,394,2.5399999618530273,2.5653999614715577,2.5653999614715577,2.527299962043762,true,false,10.007599849700956,0.9990877449461614,10026.745269112416,clinical_study,https://www.globenewswire.com/news-release/2025/06/09/3095788/0/en/Results-from-Humacyte-s-V007-Pivotal-Phase-3-AV-Access-Study-Highlighted-by-Presentation-at-the-Society-for-Vascular-Surgery-Meeting.html
48,2025-06-10T08:00:00.000Z,pre_market,2025-06-10T14:26:00.000Z,2025-06-10T14:26:00.000Z,MBX,LONG,86,11.645000457763672,11.586775455474854,11.761450462341308,11.586775455474854,false,true,-5.007350196838367,-0.4993993626489751,10021.737918915578,clinical_study,https://www.globenewswire.com/news-release/2025/06/10/3096537/0/en/MBX-Biosciences-to-Present-at-the-American-Diabetes-Association-85th-Scientific-Sessions.html
49,2025-06-10T09:01:00.000Z,pre_market,2025-06-10T14:26:00.000Z,2025-06-10T14:54:00.000Z,MYNZ,LONG,488,2.049999952316284,2.070499951839447,2.070499951839447,2.0397499525547027,true,false,10.003999767303519,0.9982300323800547,10031.741918682881,clinical_study,https://www.globenewswire.com/news-release/2025/06/10/3096780/0/en/Mainz-Biomed-Initiates-Feasibility-Study-of-Biomarker-Panel-in-Pancreatic-Cancer-Project.html
50,2025-06-10T16:00:00.000Z,regular_market,2025-06-10T16:05:00.000Z,2025-06-10T16:29:00.000Z,INMB,LONG,124,8.050000190734863,8.130500192642211,8.130500192642211,8.009750189781188,true,false,9.982000236511134,0.9950415707885077,10041.723918919392,clinical_study,https://www.globenewswire.com/news-release/2025/06/10/3097127/0/en/XPro-Reduces-Amyloid-and-Enhances-Behavior-Post-Traumatic-Brain-Injury-in-an-Animal-Model-of-Alzheimer-s-Disease-Supported-by-Department-of-Defense.html
51,2025-06-10T16:15:00.000Z,regular_market,2025-06-10T16:20:00.000Z,2025-06-10T17:13:00.000Z,CELU,LONG,522,1.9200999736785889,1.910499473810196,1.9393009734153748,1.910499473810196,false,true,-5.011460931301121,-0.4990638033633983,10036.712457988091,management_changes,https://www.globenewswire.com/news-release/2025/06/10/3097149/0/en/Celularity-Announces-Chief-Financial-Officer-Transition.html
52,2025-06-10T16:47:00.000Z,regular_market,2025-06-10T16:50:00.000Z,2025-06-10T17:11:00.000Z,VXRT,LONG,2524,0.397599995136261,0.39561199516057965,0.4015759950876236,0.39561199516057965,false,true,-5.017711938619681,-0.4999358066321954,10031.694746049472,clinical_study,https://www.globenewswire.com/news-release/2025/06/10/3097178/25416/en/Vaxart-to-Host-Conference-Call-on-June-11-at-8-30-AM-ET-to-Discuss-Topline-Results-from-Its-Phase-I-Norovirus-Trial.html
53,2025-06-11T07:30:00.000Z,pre_market,2025-06-11T14:26:00.000Z,2025-06-11T14:26:00.000Z,VXRT,LONG,1839,0.5453000068664551,0.5425735068321228,0.5507530069351196,0.5425735068321228,false,true,-5.014033563137063,-0.4998191920773518,10026.680712486335,clinical_study,https://www.globenewswire.com/news-release/2025/06/11/3097455/25416/en/Vaxart-Reports-Positive-Clinical-Data-Demonstrating-that-its-Second-Generation-Vaccine-Technology-Produces-Much-Stronger-Antibody-Responses-than-its-First-Generation-Technology.html
54,2025-06-11T08:00:00.000Z,pre_market,2025-06-11T14:26:00.000Z,2025-06-11T14:27:00.000Z,PCRX,LONG,40,24.68600082397461,24.562570819854738,24.932860832214356,24.562570819854738,false,true,-4.937200164794859,-0.49240624154377527,10021.74351232154,clinical_study,https://www.globenewswire.com/news-release/2025/06/11/3097504/0/en/Pacira-BioSciences-Unveils-Three-Year-Clinical-Data-Following-a-Single-Local-Administration-of-Investigational-Gene-Therapy-PCRX-201-in-Patients-with-Moderate-to-Severe-Osteoarthri.html
55,2025-06-11T09:00:00.000Z,pre_market,2025-06-11T14:26:00.000Z,2025-06-11T14:28:00.000Z,WINT,LONG,1441,0.6951000094413757,0.6916245093941689,0.7020510095357895,0.6916245093941689,false,true,-5.0081955680251,-0.4997329618212259,10016.735316753515,partnerships,https://www.globenewswire.com/news-release/2025/06/11/3097588/0/en/Windtree-Receives-Offer-for-Its-Preclinical-Oncology-Drug-Candidate.html
56,2025-06-11T09:25:00.000Z,pre_market,2025-06-11T14:26:00.000Z,2025-06-11T14:31:00.000Z,CAPR,LONG,77,12.890000343322754,13.01890034675598,13.01890034675598,12.82555034160614,true,false,9.925300264358466,0.990871771140631,10026.660617017873,regulatory_filings,https://www.globenewswire.com/news-release/2025/06/11/3097631/0/en/Capricor-Therapeutics-Announces-Key-Regulatory-Updates-for-its-Duchenne-Muscular-Dystrophy-Program.html
57,2025-06-11T16:20:00.000Z,regular_market,2025-06-11T16:25:00.000Z,2025-06-11T16:41:00.000Z,ALVO,SHORT,99,10.062000274658203,10.112310276031494,9.96138027191162,10.112310276031494,false,true,-4.980690135955754,-0.49674466167750964,10021.679926881918,shares_issue,https://www.globenewswire.com/news-release/2025/06/11/3097948/0/is/%C3%96ll-br%C3%A9f-afhent-kaupendum-%C3%AD-hlutafj%C3%A1r%C3%BAtbo%C3%B0i-Alvotech.html
58,2025-06-12T02:01:00.000Z,after_market,2025-06-12T14:26:00.000Z,2025-06-12T14:26:00.000Z,EDIT,LONG,493,2.0299999713897705,2.050299971103668,2.050299971103668,2.0198499715328215,true,false,10.007899858951472,0.9986249742527216,10031.687826740868,clinical_study,https://www.globenewswire.com/news-release/2025/06/12/3098060/0/en/Editas-Medicine-Reports-Proprietary-Targeted-Lipid-Nanoparticle-Delivery-in-Non-Human-Primates-Enables-In-Vivo-HBG1-2-Promoter-Editing-for-Sickle-Cell-Disease-and-Beta-Thalassemia-.html
59,2025-06-13T08:30:00.000Z,pre_market,2025-06-13T14:26:00.000Z,2025-06-13T14:27:00.000Z,TLSA,LONG,639,1.5678000450134277,1.5599610447883605,1.583478045463562,1.5599610447883605,false,true,-5.009121143817959,-0.49932984661518726,10026.67870559705,clinical_study,https://www.globenewswire.com/news-release/2025/06/13/3099003/0/en/Tiziana-Life-Sciences-to-Present-at-the-Bio-International-Convention.html
60,2025-06-13T09:00:00.000Z,pre_market,2025-06-13T14:26:00.000Z,2025-06-13T14:47:00.000Z,RAPT,LONG,1003,0.9995999932289124,1.0095959931612015,1.0095959931612015,0.9946019932627678,true,false,10.025987932086036,0.9999311064479776,10036.704693529136,changes_in_companys_own_shares,https://www.globenewswire.com/news-release/2025/06/13/3099033/0/en/RAPT-Therapeutics-Announces-Effective-Date-for-1-for-8-Reverse-Stock-Split.html
61,2025-06-13T10:30:00.000Z,pre_market,2025-06-13T14:26:00.000Z,2025-06-13T14:27:00.000Z,TLSA,LONG,640,1.5678000450134277,1.5599610447883605,1.583478045463562,1.5599610447883605,false,true,-5.016960144043026,-0.49986128886282366,10031.687733385093,clinical_study,https://www.globenewswire.com/news-release/2025/06/13/3099102/0/en/Tiziana-Life-Sciences-Expands-Phase-2-Clinical-Trial-of-Intranasal-Foralumab-with-Commencement-of-First-Patient-Dosing-at-Weill-Cornell-Multiple-Sclerosis-Center.html
62,2025-06-16T07:02:00.000Z,pre_market,2025-06-16T14:26:00.000Z,2025-06-16T14:27:00.000Z,OCGN,SHORT,827,1.2120000123977661,1.2180600124597547,1.1998800122737885,1.2180600124597547,false,true,-5.011620051264565,-0.49957895266078456,10026.67611333383,clinical_study,https://www.globenewswire.com/news-release/2025/06/16/3099710/0/en/Ocugen-Inc-Announces-U-S-FDA-Clearance-of-Investigational-New-Drug-Amendment-to-Initiate-Phase-2-3-Pivotal-Confirmatory-Clinical-Trial-of-OCU410ST-Modifier-Gene-Therapy-Candidate-f.html
63,2025-06-16T08:00:00.000Z,pre_market,2025-06-16T14:26:00.000Z,2025-06-16T14:33:00.000Z,XFOR,LONG,361,2.7699999809265137,2.7561499810218812,2.797699980735779,2.7561499810218812,false,true,-4.999849965572306,-0.49865477941621433,10021.676263368257,clinical_study,https://www.globenewswire.com/news-release/2025/06/16/3099765/0/en/X4-Pharmaceuticals-Presents-Positive-Phase-2-Chronic-Neutropenia-Trial-Data-in-Poster-Presentations-at-the-30th-Annual-Congress-of-the-European-Hematology-Association-EHA.html
64,2025-06-16T08:00:00.000Z,pre_market,2025-06-16T14:26:00.000Z,2025-06-16T14:30:00.000Z,MBX,SHORT,98,10.140000343322754,10.190700345039367,10.038600339889527,10.190700345039367,false,true,-4.968600168228122,-0.4957853394635787,10016.70766320003,clinical_study,https://www.globenewswire.com/news-release/2025/06/16/3099759/0/en/MBX-Biosciences-Announces-IND-Submission-of-MBX-4291-its-Long-acting-GLP1-GIP-Receptor-Co-agonist-Prodrug-for-the-Treatment-of-Obesity.html
65,2025-06-16T08:00:00.000Z,pre_market,2025-06-16T14:26:00.000Z,2025-06-16T14:38:00.000Z,IMRX,LONG,459,2.180000066757202,2.201800067424774,2.201800067424774,2.169100066423416,true,false,10.006200306415566,0.9989510169271419,10026.713863506446,clinical_study,https://www.globenewswire.com/news-release/2025/06/16/3099746/0/en/Immuneering-to-Provide-Updates-from-Phase-2a-Clinical-Trial-of-IMM-1-104-in-First-Line-Pancreatic-Cancer-Patients-on-Tuesday-June-17-2025.html
66,2025-06-16T08:00:00.000Z,pre_market,2025-06-16T14:26:00.000Z,2025-06-16T14:32:00.000Z,WINT,LONG,1816,0.5519999861717224,0.5575199860334397,0.5575199860334397,0.5492399862408638,true,false,10.024319748878527,0.9997612263937607,10036.738183255324,clinical_study,https://www.globenewswire.com/news-release/2025/06/16/3099771/0/en/Windtree-Announces-Publication-of-Istaroxime-Positive-Phase-2-SEISMiC-B-Study.html
67,2025-06-16T19:20:00.000Z,regular_market,2025-06-16T19:25:00.000Z,2025-06-16T19:40:00.000Z,PYPD,LONG,273,3.6700000762939453,3.6516500759124755,3.706700077056885,3.6516500759124755,false,true,-5.0095501041412644,-0.4991213293277779,10031.728633151182,financing_agreements,https://www.globenewswire.com/news-release/2025/06/16/3100290/0/en/PolyPid-Secures-26-7-Million-Through-Warrant-Exercise-Following-Successful-SHIELD-II-Phase-3-Trial-Results.html
68,2025-06-17T06:00:00.000Z,pre_market,2025-06-17T14:26:00.000Z,2025-06-17T14:27:00.000Z,IMRX,LONG,464,2.1593000888824463,2.148503588438034,2.1808930897712706,2.148503588438034,false,true,-5.009576206207242,-0.4993731777843781,10026.719056944976,clinical_study,https://www.globenewswire.com/news-release/2025/06/17/3100460/0/en/Immuneering-Reports-Positive-Overall-Survival-Data-for-Atebimetinib-IMM-1-104-from-Ongoing-Phase-2a-Trial-in-First-Line-Pancreatic-Cancer-Patients.html
69,2025-06-17T07:00:00.000Z,pre_market,2025-06-17T14:26:00.000Z,2025-06-17T14:34:00.000Z,MLYS,LONG,72,13.845000267028809,13.775775265693664,13.983450269699096,13.775775265693664,false,true,-4.984200096130422,-0.49709182712944683,10021.734856848845,clinical_study,https://www.globenewswire.com/news-release/2025/06/17/3100518/0/en/Mineralys-Therapeutics-Announces-Positive-Topline-Results-from-Phase-2-Explore-CKD-Trial-of-Lorundrostat-for-the-Treatment-of-Hypertension-in-Subjects-with-CKD-and-Albuminuria.html
70,2025-06-17T08:05:00.000Z,pre_market,2025-06-17T14:26:00.000Z,2025-06-17T14:30:00.000Z,IMNN,LONG,871,1.149399995803833,1.1436529958248138,1.1608939957618714,1.1436529958248138,false,true,-5.005636981725701,-0.49947808969470514,10016.72921986712,clinical_study,https://www.globenewswire.com/news-release/2025/06/17/3100614/0/en/IMUNON-Announces-PlaCCine-DNA-Vaccine-Technology-Abstract-Selected-for-Oral-Presentation-at-10th-International-Conference-on-Vaccines-Research-Development.html
71,2025-06-17T09:00:00.000Z,pre_market,2025-06-17T14:26:00.000Z,2025-06-17T14:42:00.000Z,CAPR,LONG,83,12.029999732971191,12.150299730300903,12.150299730300903,11.969849734306335,true,false,9.984899778366048,0.9968223717740177,10026.714119645487,regulatory_filings,https://www.globenewswire.com/news-release/2025/06/17/3100690/0/en/Capricor-Therapeutics-Announces-Orphan-Drug-Designation-for-Becker-Muscular-Dystrophy-and-Regulatory-Progress-for-Duchenne-Muscular-Dystrophy-Program.html
72,2025-06-17T14:55:00.000Z,regular_market,2025-06-17T15:00:00.000Z,2025-06-17T15:00:00.000Z,EYEN,LONG,237,4.230100154876709,4.2724011564254765,4.2724011564254765,4.208949654102326,true,false,10.025337367057894,0.9998626915486802,10036.739457012545,financing_agreements,https://www.globenewswire.com/news-release/2025/06/17/3101041/0/en/Eyenovia-Announces-50-Million-Investment-to-Launch-a-Hyperliquid-HYPE-token-Cryptocurrency-Treasury-Reserve-Strategy.html
73,2025-06-18T01:00:00.000Z,after_market,2025-06-18T14:26:00.000Z,2025-06-18T15:55:00.000Z,ADXN,LONG,122,8.199999809265137,8.281999807357789,8.281999807357789,8.15899981021881,true,false,10.003999767303519,0.9967380153834569,10046.743456779848,financial_results,https://www.globenewswire.com/news-release/2025/06/18/3101159/0/en/Addex-Therapeutics-to-Release-Q1-2025-Financial-Results-and-Host-Conference-Call-on-June-19-2025.html
74,2025-06-18T08:05:00.000Z,pre_market,2025-06-18T14:26:00.000Z,2025-06-18T14:48:00.000Z,IMNN,LONG,1025,0.9794999957084656,0.9746024957299232,0.9892949956655502,0.9746024957299232,false,true,-5.019937478005946,-0.4996581727801897,10041.723519301842,clinical_study,https://www.globenewswire.com/news-release/2025/06/18/3101425/0/en/IMUNON-Presents-Positive-Phase-2-Translational-Data-of-IMNN-001-in-Advanced-Ovarian-Cancer-at-ESMO-Gynaecological-Cancers-Congress-2025.html
75,2025-06-18T08:32:00.000Z,pre_market,2025-06-18T14:26:00.000Z,2025-06-18T14:27:00.000Z,EYEN,LONG,194,5.150000095367432,5.124250094890594,5.201500096321106,5.124250094890594,false,true,-4.995500092506498,-0.4974743710981811,10036.728019209337,financing_agreements,https://www.globenewswire.com/news-release/2025/06/18/3101458/0/en/Eyenovia-Announces-Appointment-of-a-Strategic-Advisor-for-Digital-Asset-Treasury-Strategy-and-Amendment-of-Debt-Agreement-with-Avenue-Capital-Group.html
76,2025-06-18T16:05:00.000Z,regular_market,2025-06-18T16:10:00.000Z,2025-06-18T16:22:00.000Z,ANNX,LONG,412,2.430999994277954,2.418844994306564,2.4553099942207335,2.418844994306564,false,true,-5.007859988212644,-0.49895344166227074,10031.720159221124,clinical_study,https://www.globenewswire.com/news-release/2025/06/18/3101903/0/en/Annexon-Bolsters-Ophthalmology-Expertise-with-Appointment-of-Retina-Specialist-Lloyd-Clark-M-D-as-Pivotal-ANX007-Program-Advances-in-Dry-Age-Related-Macular-Degeneration-AMD-with-G.html
77,2025-06-19T01:00:00.000Z,after_market,2025-06-20T14:26:00.000Z,2025-06-20T15:09:00.000Z,ADXN,LONG,113,8.819999694824219,8.775899696350098,8.908199691772461,8.775899696350098,false,true,-4.983299827575603,-0.4967542703027825,10026.736859393548,financial_results,https://www.globenewswire.com/news-release/2025/06/19/3102000/0/en/Addex-Therapeutics-Reports-Q1-2025-Financial-Results-and-Provides-Corporate-Update.html
78,2025-06-20T09:25:00.000Z,pre_market,2025-06-20T14:26:00.000Z,2025-06-20T14:28:00.000Z,CAPR,LONG,102,9.819999694824219,9.918199691772461,9.918199691772461,9.770899696350098,true,false,10.016399688720718,0.9989690393975835,10036.753259082268,clinical_study,https://www.globenewswire.com/news-release/2025/06/20/3102761/0/en/Capricor-Therapeutics-Announces-Positive-4-Year-Data-from-HOPE-2-Open-Label-Extension-Study-of-Deramiocel-in-Duchenne-Muscular-Dystrophy.html
79,2025-06-23T04:00:00.000Z,pre_market,2025-06-23T14:26:00.000Z,2025-06-23T14:39:00.000Z,ALVO,LONG,109,9.149999618530273,9.104249620437622,9.241499614715575,9.104249620437622,false,true,-4.98674979209896,-0.4968488975841311,10031.76650929017,regulatory_filings,https://www.globenewswire.com/news-release/2025/06/23/3103152/0/en/European-Medicines-Agency-Recommends-Market-Approval-of-AVT06-Alvotech-s-Proposed-Biosimilar-to-Eylea-aflibercept.html
80,2025-06-23T04:00:00.000Z,pre_market,2025-06-23T14:26:00.000Z,2025-06-23T14:39:00.000Z,ALVO,LONG,109,9.149999618530273,9.104249620437622,9.241499614715575,9.104249620437622,false,true,-4.98674979209896,-0.49709587912366726,10026.779759498071,product_services_announcement,https://www.globenewswire.com/news-release/2025/06/23/3103152/0/is/Lyfjastofnun-Evr%C3%B3pu-m%C3%A6lir-me%C3%B0-%C3%BEv%C3%AD-a%C3%B0-veita-marka%C3%B0sleyfi-fyrir-AVT06-fyrirhuga%C3%B0a-hli%C3%B0st%C3%A6%C3%B0u-Alvotech-vi%C3%B0-augnlyfi%C3%B0-Eylea.html
81,2025-06-23T04:00:00.000Z,pre_market,2025-06-23T14:26:00.000Z,2025-06-23T14:39:00.000Z,ALVO,LONG,109,9.149999618530273,9.104249620437622,9.241499614715575,9.104249620437622,false,true,-4.98674979209896,-0.49734310633233564,10021.793009705973,regulatory_filings,https://www.globenewswire.com/news-release/2025/06/23/3103150/0/en/European-Medicines-Agency-Recommends-Market-Approval-of-AVT06-Alvotech-s-Proposed-Biosimilar-to-Eylea-aflibercept.html
82,2025-06-23T07:00:00.000Z,pre_market,2025-06-23T14:26:00.000Z,2025-06-23T14:35:00.000Z,CDTX,LONG,24,40.529998779296875,40.32734878540039,40.93529876708985,40.32734878540039,false,true,-4.863599853515666,-0.4853023654355398,10016.929409852457,clinical_study,https://www.globenewswire.com/news-release/2025/06/23/3103267/0/en/Cidara-Therapeutics-Announces-Positive-Topline-Results-from-its-Phase-2b-NAVIGATE-Trial-Evaluating-CD388-a-Non-Vaccine-Preventative-of-Seasonal-Influenza.html
83,2025-06-23T08:00:00.000Z,pre_market,2025-06-23T14:26:00.000Z,2025-06-23T15:57:00.000Z,IMMP,LONG,642,1.559999942779541,1.5521999430656432,1.5755999422073363,1.5521999430656432,false,true,-5.007599816322372,-0.4999136573126885,10011.921810036134,clinical_study,https://www.globenewswire.com/news-release/2025/06/23/3103327/0/en/Immutep-Announces-Positive-Update-from-Phase-I-Study-of-IMP761-a-First-in-Class-LAG-3-Agonist-Antibody-for-Autoimmune-Diseases.html
84,2025-06-23T08:00:00.000Z,pre_market,2025-06-23T14:26:00.000Z,2025-06-23T14:30:00.000Z,RAPT,LONG,130,7.650000095367432,7.611750094890595,7.726500096321106,7.611750094890595,false,true,-4.972500061988798,-0.49665790008510385,10006.949309974145,management_changes,https://www.globenewswire.com/news-release/2025/06/23/3103308/0/en/RAPT-Therapeutics-Names-Two-Industry-Veterans-to-its-Board-of-Directors.html
85,2025-06-23T08:00:00.000Z,pre_market,2025-06-23T14:26:00.000Z,2025-06-23T14:50:00.000Z,MBX,LONG,102,9.739999771118164,9.837399768829346,9.837399768829346,9.691299772262573,true,false,9.9347997665406,0.9927900560701719,10016.884109740686,management_changes,https://www.globenewswire.com/news-release/2025/06/23/3103333/0/en/MBX-Biosciences-Appoints-Andreas-Moraitis-M-D-as-Senior-Vice-President-of-Clinical-Development.html
86,2025-06-23T08:05:00.000Z,pre_market,2025-06-23T14:26:00.000Z,2025-06-23T14:27:00.000Z,CADL,LONG,215,4.650000095367432,4.626750094890594,4.696500096321106,4.626750094890594,false,true,-4.998750102520004,-0.4990324384065785,10011.885359638165,management_changes,https://www.globenewswire.com/news-release/2025/06/23/3103352/0/en/Candel-Therapeutics-Appoints-Charles-Schoch-as-Chief-Financial-Officer.html
87,2025-06-23T08:05:00.000Z,pre_market,2025-06-23T14:26:00.000Z,2025-06-23T15:04:00.000Z,NKGN,LONG,4004,0.25,0.24875,0.2525,0.24875,false,true,-5.005000000000004,-0.49990584392597237,10006.880359638166,clinical_study,https://www.globenewswire.com/news-release/2025/06/23/3103355/0/en/NKGen-Biotech-Announces-International-and-U-S-Expansion-of-Phase-1-2a-Troculeucel-Alzheimer-s-Trial-with-Activation-of-Clinical-Sites-in-Canada-and-Florida.html
88,2025-06-23T08:30:00.000Z,pre_market,2025-06-23T14:26:00.000Z,2025-06-23T14:26:00.000Z,EYEN,LONG,173,5.770699977874756,5.741846477985382,5.828406977653503,5.741846477985382,false,true,-4.991655480861725,-0.4988223403764383,10001.888704157303,financing_agreements,https://www.globenewswire.com/news-release/2025/06/23/3103404/0/en/Eyenovia-Announces-Closing-of-50-Million-Private-Placement-Successful-Accumulation-of-More-Than-One-Million-HYPE-Tokens-and-Update-on-its-Optejet-Development-Program.html
89,2025-06-23T16:05:00.000Z,regular_market,2025-06-23T16:10:00.000Z,2025-06-23T16:13:00.000Z,IOVA,LONG,529,1.8899999856948853,1.8805499857664107,1.908899985551834,1.8805499857664107,false,true,-4.999049962163014,-0.49981059678110085,9996.88965419514,corporate_action,https://www.globenewswire.com/news-release/2025/06/23/3103831/0/en/Iovance-Biotherapeutics-Reports-Inducement-Grants-under-NASDAQ-Listing-Rule-5635-c-4.html
90,2025-06-23T16:15:00.000Z,regular_market,2025-06-23T16:20:00.000Z,2025-06-23T16:28:00.000Z,CDTX,SHORT,23,41.8849983215332,41.46614833831787,41.46614833831787,42.094423313140865,true,false,9.633549613952617,0.9636546913279121,10006.523203809093,shares_issue,https://www.globenewswire.com/news-release/2025/06/23/3103844/0/en/Cidara-Announces-Proposed-Public-Offering-of-Common-Stock.html
91,2025-06-23T16:50:00.000Z,regular_market,2025-06-23T16:55:00.000Z,2025-06-23T16:58:00.000Z,SCLX,LONG,216,4.630000114440918,4.676300115585327,4.676300115585327,4.606850113868713,true,false,10.000800247192444,0.9994280774150935,10016.524004056286,corporate_action,https://www.globenewswire.com/news-release/2025/06/23/3103857/0/en/Scilex-Holding-Company-Announces-Deferral-of-Record-Date-for-its-Previously-Announced-Dividend-of-Preferred-Stock-Exchangeable-for-up-to-10-of-Scilex-s-Ownership-Interest-in-Semnur.html
92,2025-06-24T06:30:00.000Z,pre_market,2025-06-24T14:26:00.000Z,2025-06-24T14:39:00.000Z,LGVN,LONG,814,1.2300000190734863,1.2423000192642213,1.2423000192642213,1.223850018978119,true,false,10.012200155258258,0.9995683284145,10026.536204211545,clinical_study,https://www.globenewswire.com/news-release/2025/06/24/3104065/0/en/Longeveron-Announces-Completion-of-Enrollment-of-Pivotal-Phase-2b-Clinical-Trial-Evaluating-Laromestrocel-as-a-Treatment-for-Hypoplastic-Left-Heart-Syndrome-HLHS.html
93,2025-06-24T09:00:00.000Z,pre_market,2025-06-24T14:26:00.000Z,2025-06-24T14:26:00.000Z,CAPR,LONG,116,8.619999885559082,8.576899886131287,8.706199884414673,8.576899886131287,false,true,-4.999599933624268,-0.4986368005657065,10021.53660427792,regulatory_filings,https://www.globenewswire.com/news-release/2025/06/24/3104316/0/en/Capricor-Therapeutics-Provides-Regulatory-Update-on-Deramiocel-BLA-for-Duchenne-Muscular-Dystrophy.html
94,2025-06-24T09:05:00.000Z,pre_market,2025-06-24T14:26:00.000Z,2025-06-24T14:33:00.000Z,CADL,SHORT,206,4.849999904632568,4.801499905586243,4.801499905586243,4.874249904155731,true,false,9.99099980354301,0.9969528823831392,10031.527604081464,shares_issue,https://www.globenewswire.com/news-release/2025/06/24/3104329/0/en/Candel-Therapeutics-Announces-15-million-Registered-Direct-Offering-of-Common-Stock.html
95,2025-06-24T20:00:00.000Z,after_market,2025-06-25T14:26:00.000Z,2025-06-25T14:26:00.000Z,CDTX,SHORT,20,49,48.51,48.51,49.245,true,false,9.80000000000004,0.9769200052854138,10041.327604081464,shares_issue,https://www.globenewswire.com/news-release/2025/06/25/3104754/0/en/Cidara-Announces-Pricing-of-Upsized-Public-Offering-of-Common-Stock.html
96,2025-06-25T04:00:00.000Z,pre_market,2025-06-25T14:26:00.000Z,2025-06-25T14:26:00.000Z,ALVO,SHORT,109,9.199999809265137,9.245999808311462,9.107999811172485,9.245999808311462,false,true,-5.013999896049414,-0.49933635209863997,10036.313604185414,clinical_study,https://www.globenewswire.com/news-release/2025/06/25/3104833/0/en/Positive-Top-Line-Results-from-Confirmatory-Efficacy-Study-for-Proposed-Biosimilar-to-Xolair-omalizumab.html
97,2025-06-25T04:00:00.000Z,pre_market,2025-06-25T14:26:00.000Z,2025-06-25T14:26:00.000Z,ALVO,SHORT,109,9.199999809265137,9.245999808311462,9.107999811172485,9.245999808311462,false,true,-5.013999896049414,-0.49958581345629144,10031.299604289365,clinical_study,https://www.globenewswire.com/news-release/2025/06/25/3104830/0/en/Positive-Top-Line-Results-from-Confirmatory-Efficacy-Study-for-Proposed-Biosimilar-to-Xolair-omalizumab.html
98,2025-06-25T04:00:00.000Z,pre_market,2025-06-25T14:26:00.000Z,2025-06-25T19:45:00.000Z,ALVO,LONG,109,9.199999809265137,9.153999810218812,9.291999807357788,9.153999810218812,false,true,-5.013999896049414,-0.4998355241932398,10026.285604393315,clinical_study,https://www.globenewswire.com/news-release/2025/06/25/3104830/0/is/J%C3%A1kv%C3%A6%C3%B0-ni%C3%B0ursta%C3%B0a-%C3%BAr-kl%C3%ADn%C3%ADskri-ranns%C3%B3kn-fyrir-fyrirhuga%C3%B0a-hli%C3%B0st%C3%A6%C3%B0u-Alvotech-vi%C3%B0-l%C3%ADft%C3%A6knilyfi%C3%B0-Xolair.html
99,2025-06-25T08:00:00.000Z,pre_market,2025-06-25T14:26:00.000Z,2025-06-25T16:25:00.000Z,BCDA,LONG,462,2.1700000762939453,2.1591500759124758,2.191700077056885,2.1591500759124758,false,true,-5.012700176238932,-0.4999558534461125,10021.272904217076,patents,https://www.globenewswire.com/news-release/2025/06/25/3105029/0/en/BioCardia-Announces-New-United-States-Patent-for-Helix-Biotherapeutic-Delivery-System.html
100,2025-06-25T08:00:00.000Z,pre_market,2025-06-25T14:26:00.000Z,2025-06-25T14:26:00.000Z,ICCC,LONG,140,7.130000114440918,7.094350113868713,7.201300115585327,7.094350113868713,false,true,-4.991000080108687,-0.49804053115931135,10016.281904136968,management_changes,https://www.globenewswire.com/news-release/2025/06/25/3105042/0/en/ImmuCell-Embarks-on-CEO-Succession-Planning-Process.html
101,2025-06-25T08:00:00.000Z,pre_market,2025-06-25T14:26:00.000Z,2025-06-25T14:29:00.000Z,EVAX,LONG,420,2.3819000720977783,2.4057190728187563,2.4057190728187563,2.3699905717372896,true,false,10.003980302810751,0.9987718395464553,10026.285884439778,clinical_study,https://www.globenewswire.com/news-release/2025/06/25/3105043/0/en/Evaxion-expands-R-D-pipeline-with-new-vaccine-program-targeting-Group-A-Streptococcus.html
102,2025-06-25T08:00:00.000Z,pre_market,2025-06-25T14:26:00.000Z,2025-06-25T15:51:00.000Z,ENTX,LONG,506,1.979099988937378,1.9988909888267516,1.9988909888267516,1.969204488992691,true,false,10.0142459440231,0.9987991624659971,10036.300130383801,clinical_study,https://www.globenewswire.com/news-release/2025/06/25/3105034/0/en/OPKO-Health-and-Entera-Bio-Abstract-for-First-in-Class-Dual-GLP-1-Glucagon-Tablet-Candidate-for-Patients-with-Obesity-and-Metabolic-Disorders-Selected-for-Presentation-at-the-ENDO-.html
103,2025-06-25T08:00:00.000Z,pre_market,2025-06-25T14:26:00.000Z,2025-06-25T15:14:00.000Z,CRBP,LONG,126,7.965000152587891,8.04465015411377,8.04465015411377,7.925175151824951,true,false,10.035900192260751,0.9999601508406629,10046.336030576062,clinical_study,https://www.globenewswire.com/news-release/2025/06/25/3105004/0/en/Corbus-Pharmaceuticals-Announces-First-Patient-Dosed-with-its-Nectin-4-Targeting-ADC-CRB-701-in-Combination-with-Pembrolizumab.html
104,2025-06-25T08:30:00.000Z,pre_market,2025-06-25T14:26:00.000Z,2025-06-25T14:26:00.000Z,EYEN,LONG,95,10.470000267028809,10.417650265693664,10.574700269699097,10.417650265693664,false,true,-4.973250126838691,-0.4950312344423465,10041.362780449223,partnerships,https://www.globenewswire.com/news-release/2025/06/25/3105095/0/en/Eyenovia-Announces-Co-Branded-Validator-with-Kinetiq.html
105,2025-06-25T16:15:00.000Z,regular_market,2025-06-25T16:20:00.000Z,2025-06-25T16:49:00.000Z,DBVT,SHORT,113,8.819999694824219,8.86409969329834,8.731799697875976,8.86409969329834,false,true,-4.983299827575603,-0.4962772420968804,10036.379480621647,clinical_study,https://www.globenewswire.com/news-release/2025/06/25/3105444/0/en/DBV-Technologies-Announces-First-Subject-Screened-in-COMFORT-Toddlers-Supplemental-Safety-Study-in-Peanut-Allergic-Toddlers-1-3-Years-Old.html
106,2025-06-25T16:15:00.000Z,regular_market,2025-06-25T16:20:00.000Z,2025-06-25T16:49:00.000Z,DBVT,SHORT,113,8.819999694824219,8.86409969329834,8.731799697875976,8.86409969329834,false,true,-4.983299827575603,-0.4965236554872615,10031.39618079407,clinical_study,https://www.globenewswire.com/news-release/2025/06/25/3105444/0/fr/DBV-Technologies-annonce-le-screening-du-premier-sujet-de-l-%C3%A9tude-compl%C3%A9mentaire-d-innocuit%C3%A9-COMFORT-Toddlers-chez-les-enfants-%C3%A2g%C3%A9s-de-1-%C3%A0-3-ans-allergiques-%C3%A0-l-arachide.html
107,2025-06-26T01:00:00.000Z,after_market,2025-06-26T14:26:00.000Z,2025-06-26T16:43:00.000Z,VALN,LONG,173,5.78000020980835,5.751100208759308,5.837800211906433,5.751100208759308,false,true,-4.999700181484247,-0.49840521612102034,10026.396480612586,partnerships,https://www.globenewswire.com/news-release/2025/06/26/3105549/0/en/Valneva-Announces-Exclusive-Vaccine-Marketing-and-Distribution-Agreement-for-Germany-with-CSL-Seqirus.html
108,2025-06-26T01:00:00.000Z,after_market,2025-06-26T14:26:00.000Z,2025-06-26T16:43:00.000Z,VALN,LONG,173,5.78000020980835,5.751100208759308,5.837800211906433,5.751100208759308,false,true,-4.999700181484247,-0.49865374774993726,10021.396780431101,partnerships,https://www.globenewswire.com/news-release/2025/06/26/3105549/0/fr/Valneva-annonce-un-accord-exclusif-avec-CSL-Seqirus-pour-le-marketing-et-la-distribution-de-ses-vaccins-en-Allemagne.html
109,2025-06-26T04:15:00.000Z,pre_market,2025-06-26T14:26:00.000Z,2025-06-26T15:29:00.000Z,ALVO,LONG,105,9.475000381469727,9.427625379562377,9.569750385284424,9.427625379562377,false,true,-4.974375200271703,-0.49637543640475584,10016.42240523083,financing_agreements,https://www.globenewswire.com/news-release/2025/06/26/3105605/0/en/Alvotech-s-Lenders-Lower-Interest-on-Senior-Secured-Term-Loan-Facility.html
110,2025-06-26T04:15:00.000Z,pre_market,2025-06-26T14:26:00.000Z,2025-06-26T15:29:00.000Z,ALVO,LONG,105,9.475000381469727,9.427625379562377,9.569750385284424,9.427625379562377,false,true,-4.974375200271703,-0.4966219473405952,10011.448030030557,financing_agreements,https://www.globenewswire.com/news-release/2025/06/26/3105605/0/is/L%C3%A1nveitendur-Alvotech-l%C3%A6kka-vexti-%C3%A1-langt%C3%ADmaskuldum-f%C3%A9lagsins.html
111,2025-06-26T04:15:00.000Z,pre_market,2025-06-26T14:26:00.000Z,2025-06-26T15:29:00.000Z,ALVO,LONG,105,9.475000381469727,9.427625379562377,9.569750385284424,9.427625379562377,false,true,-4.974375200271703,-0.4968687032435727,10006.473654830284,financing_agreements,https://www.globenewswire.com/news-release/2025/06/26/3105605/0/sv/Alvotechs-l%C3%A5ngivare-s%C3%A4nker-r%C3%A4ntan-p%C3%A5-senior-s%C3%A4kerst%C3%A4lld-l%C3%A5nefacilitet.html
112,2025-06-26T04:15:00.000Z,pre_market,2025-06-26T14:26:00.000Z,2025-06-26T15:29:00.000Z,ALVO,LONG,105,9.475000381469727,9.427625379562377,9.569750385284424,9.427625379562377,false,true,-4.974375200271703,-0.49711570447901926,10001.499279630012,financing_agreements,https://www.globenewswire.com/news-release/2025/06/26/3105606/0/en/Alvotech-s-Lenders-Lower-Interest-on-Senior-Secured-Term-Loan-Facility.html
113,2025-06-26T07:00:00.000Z,pre_market,2025-06-26T14:26:00.000Z,2025-06-26T19:06:00.000Z,RVVTF,LONG,66676,0.014999999664723873,0.015149999661371111,0.015149999661371111,0.014924999666400254,true,false,10.001399776451262,0.9999900511737322,10011.500679406463,clinical_study,https://www.globenewswire.com/news-release/2025/06/26/3105718/0/en/Revive-Therapeutics-Nears-Completion-of-Key-Nerve-Agent-Countermeasure-Study-with-Canadian-Department-of-National-Defence-Highlighting-Significant-Stockpiling-Opportunity.html
114,2025-06-26T07:00:00.000Z,pre_market,2025-06-26T14:26:00.000Z,2025-06-26T15:04:00.000Z,CRSP,LONG,21,46.099998474121094,46.56099845886231,46.56099845886231,45.86949848175049,true,false,9.680999679565495,0.9669878662126244,10021.181679086028,clinical_study,https://www.globenewswire.com/news-release/2025/06/26/3105698/0/en/CRISPR-Therapeutics-Reports-Positive-Additional-Phase-1-Data-for-CTX310-Targeting-ANGPTL3-and-Provides-Update-on-In-Vivo-Cardiovascular-Pipeline.html
115,2025-06-26T08:00:00.000Z,pre_market,2025-06-26T14:26:00.000Z,2025-06-26T14:43:00.000Z,ARQT,LONG,69,14.454999923706055,14.382724924087524,14.599549922943115,14.382724924087524,false,true,-4.986974973678594,-0.49764340507729676,10016.19470411235,product_services_announcement,https://www.globenewswire.com/news-release/2025/06/26/3105808/0/en/Arcutis-ZORYVE-roflumilast-Cream-0-15-Receives-Strong-Recommendation-in-American-Academy-of-Dermatology-Updated-Guidelines-for-Adult-Atopic-Dermatitis.html
116,2025-06-26T08:00:00.000Z,pre_market,2025-06-26T14:26:00.000Z,2025-06-26T15:19:00.000Z,ENTX,LONG,503,1.9900000095367432,2.0099000096321107,2.0099000096321107,1.9800500094890594,true,false,10.009700047969863,0.9993515844755074,10026.204404160319,clinical_study,https://www.globenewswire.com/news-release/2025/06/26/3105791/0/en/Entera-Bio-Data-for-EB613-Effects-on-Trabecular-and-Cortical-Bone-in-Post-Menopausal-Women-with-Osteoporosis-Selected-for-Oral-Presentation-at-ASBMR-2025-Annual-Meeting.html
117,2025-06-26T08:19:00.000Z,pre_market,2025-06-26T14:26:00.000Z,2025-06-26T14:52:00.000Z,BMRA,LONG,327,3.059999942779541,3.0446999430656434,3.0905999422073362,3.0446999430656434,false,true,-5.00309990644452,-0.4990023846280763,10021.201304253875,management_changes,https://www.globenewswire.com/news-release/2025/06/26/3105827/0/en/Clinical-Diagnostics-Industry-Leader-Scott-Madel-Joins-Biomerica-s-Team-as-Chief-Commercial-Officer.html
118,2025-06-26T09:05:00.000Z,pre_market,2025-06-26T14:26:00.000Z,2025-06-26T14:35:00.000Z,LGVN,LONG,759,1.3200000524520874,1.313400052189827,1.3332000529766084,1.313400052189827,false,true,-5.009400199055625,-0.4998802086661204,10016.191904054818,management_changes,https://www.globenewswire.com/news-release/2025/06/26/3105920/0/en/Longeveron-Appoints-Than-Powell-as-Chief-Business-Officer.html
119,2025-06-26T16:05:00.000Z,regular_market,2025-06-26T16:10:00.000Z,2025-06-26T16:12:00.000Z,WINT,LONG,2320,0.4316999912261963,0.43601699113845827,0.43601699113845827,0.4295414912700653,true,false,10.015439796447785,0.9999249108229716,10026.207343851265,partnerships,https://www.globenewswire.com/news-release/2025/06/26/3106221/0/en/Windtree-Advances-Lower-Cost-Manufacturing-of-PHEXXI-Evofem-s-Hormone-Free-On-Demand-Prescription-Contraceptive-Gel.html
120,2025-06-26T17:15:00.000Z,regular_market,2025-06-26T17:20:00.000Z,2025-06-26T17:22:00.000Z,CDTX,SHORT,20,47.79999923706055,48.038999233245846,47.32199924468994,48.038999233245846,false,true,-4.7799999237059865,-0.4767505557958962,10021.427343927558,shares_issue,https://www.globenewswire.com/news-release/2025/06/26/3106294/0/en/Cidara-Announces-Closing-of-Upsized-Public-Offering-and-Full-Exercise-of-Underwriters-Option-to-Purchase-Additional-Shares.html
121,2025-06-27T12:16:00.000Z,pre_market,2025-06-27T14:26:00.000Z,2025-06-27T14:26:00.000Z,INMB,LONG,93,10.767600059509277,10.87527606010437,10.87527606010437,10.713762059211732,true,false,10.013868055343687,0.9992456874330929,10031.441211982903,financing_agreements,https://www.globenewswire.com/news-release/2025/06/27/3106725/0/en/INmune-Bio-Inc-Announces-Approximately-19-Million-Registered-Direct-Offering-Priced-At-the-Market-Under-Nasdaq-Rules.html
